Slide 1: Q4 & FY 2024 Earnings Call Presentation
Q4 & FY 2024 Earnings Call Presentation March │ 2025 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Auna S.A. (“Auna” or the “Company”) solely for use at this presentation. This presentation is confidential to the recipient. Accordingly, any attempt to copy, summarize or distribute this presentation or any portion hereof in any form to any other pa
Slide 3: Today's Participants
Today’s Participants +30 +20 +25 Jesus Zamora Gisele Remy Lorenzo Massart Executive Chairman of the Board and Chief Financial Officer and Executive Vice President, Strategy and President Executive Vice President Equity Capital Markets • Member of the Board since 2008 and President • Chief Financial
Slide 4: 4Q24 and FY24 Highlights
4Q24 and FY24 Highlights 4Q24 Adjusted EBITDA1 +19% YoY (or +28% FXN2) with 23.9% margin, +3.1p.p. vs 4Q23; Successfully FY24 Adjusted EBITDA1 +20.4% YoY (or +20.1% FXN) YoY with 22.6%, +1.4 p.p. vs FY23 met FY24 Consistent and strong results in Peru, a mature and predictable business that continues
Slide 5: Robust consecutive quarterly performance, meeting FY 2024 guidance
Robust consecutive quarterly performance, meeting FY 2024 guidance with +20.1% FXN YoY growth Consolidated 4Q24 Consolidated FY24 Revenue (S/) Adjusted EBITDA (S/) Revenue (S/) Adjusted EBITDA (S/) 1,063 Mn 254 Mn 4,386 Mn 993 Mn +4% +19% +13% +20% +11% FXN YoY +28% FXN YoY +12% FXN YoY +20.1% FXN Y
Slide 6: Q4 and FY 2024 Results by Segment
Q4 and FY 2024 Results by Segment 6
Slide 7: Healthcare Services Mexico maintains momentum
Healthcare Services Mexico maintains momentum with Revenue and Adj EBITDA YoY growth driven by volume and ticket mix in hospitalizations, ICU and surgeries External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 27% of FY24 Revenues 41% of FY24 Adj. EBITDA 35.9% 34.7% 29.0% 33.9% 34.3% +9%
Slide 8: Peruvian healthcare and Oncosalud segments outperform
Peruvian healthcare and Oncosalud segments outperform by capturing a broader population, optimizing pricing and increasing plan memberships External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 40% of FY24 Revenues 37% of FY24 Adj. EBITDA 21.2% 21.6% 21.7% 15.8% +10% 17.9% +13% -1% +33%
Slide 9: Colombia's results benefit from risk sharing models and increased ICU beds
Colombia´s results benefit from risk sharing models and increased ICU beds, offsetting the negative effects from A/R provisions External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 33% of FY24 Revenues 22% of FY24 Adj. EBITDA 17.3% 18.6% 16.3% 15.1% 12.4% +14% (L.C) +14% (L.C) +6% +23%
Slide 10: Q4 & FY 2024 Consolidated Results
Q4 & FY 2024 Consolidated Results 10
Slide 11: Strong consolidated double-digit revenue growth
Strong consolidated double-digit revenue growth ▪ 4Q24 revenues increased 9% in L.C. in Mexico, 14% in L.C. in Colombia, and 10% in Peru vs 4Q23 ▪ Mexico HC services grew on service mix and pricing; Peru HC services on mix and high complexity; Colombia focused on risk sharing models and diversifying
Slide 12: Adjusted EBITDA +28% FXN YoY
Adjusted EBITDA1 +28% FXN in YoY driven by both revenue growth, a more profitable mix, and continued operating efficiencies in our integrated platform ▪ Adjusted EBITDA Margin1 of 23.9% in 4Q24 vs 20.9% in 4Q23 ▪ In Peru, Adjusted EBITDA1 delivered 33% YoY growth, with an Adjusted EBITDA Margin incr
Slide 13: Adjusted EBITDA +20.1% FXN, meeting guidance for FY24
Adjusted EBITDA1 +20.1% FXN, meeting guidance for FY24 ▪ All segments increased Adjusted EBITDA1 YoY, especially Peru, which grew 51% YoY, with an Adjusted EBITDA Margin1 of 21.2% in FY24, up from 15.8% in FY23 ▪ Mexico +10% L.C. and Colombia +6% L.C. in YoY Adjusted EBITDA1 Bridge (S/ Mn, %) Consol
Slide 14: Positive Adjusted Net Income in 4Q24
Positive Adjusted Net Income1 in 4Q24 Adjusted Net Income1 bridge: 4Q’23 vs 4Q’24 (S/ Mn) 36 200 220 Adjusted 36 Adjusted EPS2 : 60 73 EPS2 : S/ 0.05 S/ 0.47 -6 Adj. Net Operating Profit Fx variance Net interest Income tax Non-cash and Adj. Net Income 4Q23 1 expense extraordinary Income 4Q24 1 items
Slide 15: Positive Adjusted Net Income for a fourth consecutive quarter
Auna maintained positive Adjusted Net Income1 for a fourth consecutive quarter and in FY24 Adjusted Net Income1 bridge FY23’ vs FY24’: (S/ Mn) 30 203 200 118 146 223 Adjusted Adjusted EPS2: 14 EPS2: S/ 0.58 S/ 1.97 Adj. Net Operating Profit Fx variance Net interest Income tax Non-cash and Adj. Net I
Slide 16: End of period cash continues improving
End of period cash continues improving in consecutive quarters ▪ EoP Cash increased 18% over 3Q’24 and 49% over 2Q’24 ▪ Maintenance CAPEX at 3.7% of revenues Cash flow bridge (S/ Mn) Free Cash Flow S/432 Net Cash Flows from Net Cash Flows used in Operations Investments Net Cash Flows in Financing S/
Slide 17: Healthy debt maturity profile with leverage ratio improving to 3.6x
Healthy debt maturity profile with leverage ratio improving to 3.6x Debt Structure Highlights Debt by Type (%) Debt by Currency (%) ✓ Steady deleveraging since the 2022 acquisition of Monterrey Consolidated Debt: S/ 3,768 network and IMAT Oncomedica Term Loan 32% 9% Senior Notes 50% ✓ More than half
Slide 18: In 2025, Auna's goal is to maintain 20% FXN Adjusted EBITDA growth
We are committed to advancing healthcare through our value-based care model, enhancing medical resolution, optimizing our resources, and driving sustainable growth. “In 2025, Peru will continue to be a strong contributor to Auna´s growth backed by its vertically integrated model at scale that has pr
Slide 19: Q&A
Q&A qund
Slide 20: Exhibits
Exhibits qund
Slide 21: Consolidated Balance Sheet
Consolidated Balance Sheet (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Dec-24 Δ Dec-24 Dec-24 Δ Dec-24 Dec-24 Dec-23 Dec-24 Dec-23 (USD) vs Dec-23 (USD) vs Dec-23 Assets Liabilities Current assets Current liabilities Cash and cash equivalents 63 236 241 (5)
Slide 22: Consolidated Statement of Income (1/2)
Consolidated Statement of Income (1/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 4Q'24 Δ 4Q'24 vs Δ FY 24 vs 4Q'24 FY 24 (USD) 4Q'23 FY 23 Revenue Healthcare Services Mexico 71 268 1,195 -6% 6% Healthcare Services Colombia 94 353 1,443 6% 21% Healthcare Se
Slide 23: Consolidated Statement of Income (2/2)
Consolidated Statement of Income (2/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 4Q'24 Δ 4Q'24 vs Δ FY 24 vs 4Q'24 FY 24 (USD) 4Q'23 FY 23 Share of profit of equity accounted investees 1 2 9 56% 40% Profit (loss) before tax 10 37 184 122% 248% Income tax e
Slide 24: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) FY 24 Δ FY 24 FY 24 Δ FY 24 FY 24 FY 23 FY 24 FY 23 (USD) vs FY 23 (USD) vs FY 23 Cash flows from operating activities Cash flows from investing activities (Loss) profit for the per
Slide 25: Consolidated Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Consolidated Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre- operating
Slide 26: Consolidated Peru Adjusted EBITDA reconciliation
Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru Segment Adjusted EBITDA plus Oncosalud Peru Segment Ad
Slide 27: Adjusted Net Income reconciliation
Adjusted Net Income reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below. 4Q'24 4Q'24 4Q'23 FY 24 FY 23 (USD) Net Income (Loss) 6 24 (219) 124 (214)
Slide 28: Adjusted Basic and Diluted Earnings per Share
Adjusted Basic and Diluted Earnings per Share (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Inc
Slide 29: Net Debt reconciliation
Net Debt reconciliation (Figures in millions of Soles, unless expressed otherwise) Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents. 2023 2024 (+) Loans and borrowings 3,762 3,620 Short term debt 385 654 Long term debt 3,376 2,966 (+) Lease Liabilities 158 148 Gross Debt
Slide 30: Leverage ratio reconciliation
Leverage ratio reconciliation (Figures in millions of Soles, unless expressed otherwise) Leverage Ratio: is calculated as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted
Slide 31: Key Operational Metrics – Oncosalud Peru & Healthcare Services
Key Operational Metrics – Oncosalud Peru & Healthcare Services 1) As of period end and as reported to the National Superintendence of Health Susalud. Δ FY 24 vs Includes Oncology plans and Health plans. FY 24 FY 23 2) Includes active plan members and inactive members. Inactive members are defined as
Slide 32: Trends in Key Financial Metrics
Trends in Key Financial Metrics (Figures in millions of Soles, unless expressed otherwise) 4Q'22 1Q'23 2Q'23 3Q'23 4Q'23 1Q'24 2Q'24 3Q'24 4Q'24 Revenue Oncosalud Peru 215 221 230 237 244 253 269 273 276 Healthcare Services Peru 190 212 217 230 225 241 255 255 245 Healthcare Services Colombia 237 25
Slide 33: Investor Relations
Investor Relations contact@aunainvestors.com www.aunainvestors.com 33